UW–Madison receives $150 million grant to lead nationwide Alzheimer’s disease study

The University of Wisconsin School of Medicine and Public Health has been awarded the largest National Institutes of Health (NIH) funding award in the history of UW–Madison . Sterling Johnson, PhD, will lead the research initiative that involves all 37 Alzheimer’s Disease Research Centers in the United States.

The Precious Gift of More

People facing Alzheimer’s disease long for more time. More memories. More days of feeling like nothing has changed. But the heartbreaking reality is that all these things are stripped away, often with little warning.
That’s why the UW Initiative to End Alzheimer’s (IEA) is pioneering the most advanced research initiatives and treatments to give people and their families hope for the future.

Pedaling to preserve memories down under with Dave and French Fry

Dave Adam continues to be a champion for Alzheimer’s disease research. Dave is a Wisconsin man who cycled across Canada last year to help raise funds for Alzheimer’s disease programs at UW–Madison. This year he’s going down under to Australia and plans to bike 2,500 miles to support the UW Initiative to End Alzheimer’s.

Announcing the IEA Innovation Fund

The UW Initiative to End Alzheimer’s (IEA) is pleased to announce the IEA Innovation Fund, providing project support for researchers from the Wisconsin Alzheimer’s Disease Research Center (ADRC) or Wisconsin Alzheimer’s Institute (WAI). The IEA Innovation Fund will help advance the University of Wisconsin–Madison’s Alzheimer’s disease researchers’ most promising ideas by providing an open door to funding opportunities that foster translational, innovative and inclusive advancements in Alzheimer’s disease research.

A closer look at lecanemab

In January, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway to treat Alzheimer’s disease. Nathaniel Chin, MD, recently interviewed Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to inform people about the research behind the new Alzheimer’s treatment, the drug’s benefits and risks, and more.